ReviewJAMA2014
Screening mammography in older women: a review.
Review in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 7 syntheses or guidelines pooled it, 235 citations in OpenAlex.
- Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis.Aging and disease · 2024Pooled it
- Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.British journal of cancer · 2024Pooled it
- Patient-Reported Factors Associated With Older Adults' Cancer Screening Decision-making: A Systematic Review.JAMA network open · 2021Pooled it
- Screening mammography use in older women according to health status: a systematic review and meta-analysis.Clinical interventions in aging · 2018Pooled it
- Breast Cancer Screening: Updated Recommendations of the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian Federation of Gynecological and Obstetrical Associations.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2017Guideline
- Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses.Journal of general internal medicine · 2016Pooled it
- Guideline
- Does Messaging for Reducing Breast Cancer Overscreening in Older Women Have Differential Responses among Medical Minimizers and Maximizers?Medical decision making : an international journal of the Society for Medical Decision Making · 2026Trial
- The effect of conflicting versus consistent messaging on older women's support for breast cancer screening cessation.Patient education and counseling · 2025Trial
- Effect of Messaging on Support for Breast Cancer Screening Cessation Among Older US Women: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Randomized Trial of Information for Older Women About Cessation of Breast Cancer Screening Invitations.Journal of general internal medicine · 2024Trial
- Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.Breast cancer research and treatment · 2022Trial
- Trial
- Effect of a Mammography Screening Decision Aid for Women 75 Years and Older: A Cluster Randomized Clinical Trial.JAMA internal medicine · 2020Trial
- Should women aged 70-74 be invited to participate in screening mammography? A report on two Australian community juries.BMJ open · 2018Trial
- Temporal trajectories of age at breast cancer diagnosis by socioeconomic and geographic factors: a 1975-2021 SEER analysis.Cancer causes & control : CCC · 2026Observational
- Should Adherence to Medical Recommendations Be a Requirement for Kidney Transplant Candidacy?The American journal of bioethics : AJOB · 2026Article
- An exploratory mixed-methods study using the ELICIT framework to identify stakeholder-informed implementation strategies for a population health platform.BMC health services research · 2026Article
- Social Drivers of Guideline-Discordant Breast Cancer Screening by Age and Mortality Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Trends and disparities in breast cancer mortality among older adults in the United States, 1999-2020.Frontiers in oncology · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
importanceGuidelines recommend individualizing screening mammography decisions for women aged 75 years and older. However, little pragmatic guidance is available to help counsel patients.
objectiveTo provide an evidence-based approach for individualizing decision-making about screening mammography in older women. EVIDENCE ACQUISITION: We searched PubMed for English-language studies in peer-reviewed journals published from January 1, 1990, to February 1, 2014, to identify risk factors for late-life breast cancer in women aged 65 years and older and to quantify the benefits and harms of screening mammography for women aged 75 years and older.
findingsAge is the major risk factor for developing and dying from breast cancer. Breast cancer risk factors that reflect hormonal exposures in the distant past, such as age at first birth or age at menarche, are less predictive of late-life breast cancer than factors indicating recent hormonal exposures such as high bone mass or obesity. Randomized trials of the benefits of screening mammography did not include women older than 74 years. Thus it is not known if screening mammography benefits older women. Observational studies favor extending screening mammography to older women who have a life expectancy of more than 10 years. Modeling studies estimate 2 fewer breast cancer deaths/1000 women who in their 70s continue biennial screening for 10 years instead of stopping screening at age 69. Potential harms of continued screening over 10 years include false-positive mammograms in approximately 200/1000 women screened and overdiagnosis (ie, finding breast cancer that would not have clinically surfaced otherwise) in approximately 13/1000 women screened. Providing information about life expectancy along with potential benefits and harms of screening may help older women's decision-making about screening mammography. CONCLUSIONS AND RELEVANCE: For women with less than a 10-year life expectancy, recommendations to stop screening mammography should emphasize increased potential harms from screening and highlight health promotion measures likely to be beneficial over the short term. For women with a life expectancy of more than 10 years, deciding whether potential benefits of screening outweigh harms becomes a value judgment for patients, requiring a realistic understanding of screening outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.